









市場行情
/
股票
/
nasdaq-yi
/

111 Inc

3.160USD

-0.533-14.44%

收盤 12/22, 16:00（美東）報價延遲15分鐘

160.13M總市值

虧損本益比TTM



111 Inc

3.160

-0.533-14.44%

概覽公司財務分析

概覽

公司

財務

分析

關於 111 Inc 公司

111 Inc is an investment holding company primarily engaged in the operation of integrated online and offline healthcare platform. The Company mainly operates its business through two segments. The Business to Customer (B2C) segment is engaged in the sale of pharmaceutical and other health and wellness products through 1 Medicine Marketplace, mobile apps, other online channels and offline pharmacies to consumers and certain enterprise customers. The Business to Business (B2B) segment is engaged in the sale of pharmaceutical products to pharmacies on 1 Pharmacy. The Company also provides customers with online consultation and electronic prescription services through the Internet hospital 1 Clinic. The Company’s products include drugs, nutritional supplements, medical supplies and devices and other products. The Company mainly conducts its business in the domestic market.

111 Inc簡介



公司代碼YI

公司名稱111 Inc

上市日期Sep 12, 2018

CEOLiu (Junling)

員工數量1238

證券類型Depository Receipt

年結日Sep 12

公司地址3-4/F, No.295 Zuchongzhi Road

城市SHANGHAI

上市交易所NASDAQ OMX - NASDAQ BASIC

國家China

郵編201203

電話862120536666

網址http://corporate.111.com.cn/

公司代碼YI

上市日期Sep 12, 2018

CEOLiu (Junling)

111 Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Junling Liu

Co-Chairman of the Board, Chief Executive Officer, Co-Founder

Dr. Gang Yu, Ph.D.

Executive Co-Chairman of the Board, Co-Founder

Mr. Yang (Luke) Chen

Director

Mr. Jun Luo

Independent Director

Mr. Jian (David) Sun

Independent Director

Mr. Nee Chuan Teo, CPA

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Junling Liu

Co-Chairman of the Board, Chief Executive Officer, Co-Founder

Dr. Gang Yu, Ph.D.

Executive Co-Chairman of the Board, Co-Founder

Mr. Yang (Luke) Chen

Director

Mr. Jun Luo

Independent Director

Mr. Jian (David) Sun

Independent Director

Mr. Nee Chuan Teo, CPA

Independent Director

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Product Revenues

3.51B

99.44%

Service Revenues

19.70M

0.56%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

Product Revenues

3.51B

99.44%

Service Revenues

19.70M

0.56%

股東統計

更新時間: 12月2日週二

持股股東

股東類型

持股股東

佔比

First Pharmacia International

8.57%

Susquehanna International Group, LLP

0.59%

Renaissance Technologies LLC

0.26%

Morgan Stanley & Co. LLC

0.10%

Geode Capital Management, L.L.C.

0.05%

其他

90.43%

持股股東

佔比

First Pharmacia International

8.57%

Susquehanna International Group, LLP

0.59%

Renaissance Technologies LLC

0.26%

Morgan Stanley & Co. LLC

0.10%

Geode Capital Management, L.L.C.

0.05%

其他

90.43%

股東類型

持股股東

佔比

Private Equity

15.64%

Corporation

8.57%

Venture Capital

7.15%

Investment Advisor

0.62%

Hedge Fund

0.26%

Research Firm

0.11%

Investment Advisor/Hedge Fund

0.05%

其他

67.61%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

1.21M

23.79%

-403.88K

2025Q2

1.99M

39.33%

-416.92K

2025Q1

2.00M

39.53%

-387.91K

2024Q4

2.26M

44.72%

+133.67K

2024Q3

1.99M

39.36%

-280.22K

2024Q2

2.17M

42.88%

-87.92K

2024Q1

2.15M

42.65%

-125.45K

2023Q4

2.16M

44.89%

-28.04K

2023Q3

2.15M

44.81%

-47.43K

2023Q2

2.05M

43.37%

+895.26K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

First Pharmacia International

434.53K

8.57%

Mar 31, 2025

Susquehanna International Group, LLP

14.77K

0.29%

+14.77K

Jun 30, 2025

Renaissance Technologies LLC

13.01K

0.26%

+200.00

+1.56%

Jun 30, 2025

Morgan Stanley & Co. LLC

5.14K

0.1%

Jun 30, 2025

UBS Financial Services, Inc.

6.12K

0.12%

+4.66K

+320.77%

Jun 30, 2025

SBI Securities Co., Ltd.

224.00

-38.00

-14.50%

Jun 30, 2025

J.P. Morgan Securities LLC

8.00

-62.00

-88.57%

Jun 30, 2025

Parametric Portfolio Associates LLC

27.00

Jun 30, 2025

Rhumbline Advisers Ltd. Partnership

22.00

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

SPDR S&P Emerging Markets Small Cap ETF

SPDR Portfolio Emerging Markets ETF

SPDR S&P Emerging Asia Pacific ETF

SPDR S&P Emerging Markets Small Cap ETF

佔比0%

SPDR Portfolio Emerging Markets ETF

佔比0%

SPDR S&P Emerging Asia Pacific ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Jan 03, 2025

Merger

10→1

Jan 03, 2025

Merger

10→1

Jan 03, 2025

Merger

10→1

Jan 03, 2025

Merger

10→1

公告日期

類型

比率

Jan 03, 2025

Merger

10→1

Jan 03, 2025

Merger

10→1

Jan 03, 2025

Merger

10→1

Jan 03, 2025

Merger

10→1

常見問題

111 Inc的前五大股東是誰？



111 Inc的前五大股東如下：
First Pharmacia International
持有股份：434.53K
佔總股份比例：8.57%。
Susquehanna International Group, LLP
持有股份：14.77K
佔總股份比例：0.29%。
Renaissance Technologies LLC
持有股份：13.01K
佔總股份比例：0.26%。
Morgan Stanley & Co. LLC
持有股份：5.14K
佔總股份比例：0.10%。
UBS Financial Services, Inc.
持有股份：6.12K
佔總股份比例：0.12%。